Archimedes Pharma wins the Scrip Award for SME Pharma Company of the Year
Archimedes Pharma Limited won the Scrip Award SME Pharma Company of the Year. The Scrip Awards are voted for by a panel of esteemed judges from the pharmaceutical industry worldwide. The judging criteria included: excellent performance across a range of activities, such as a growth in revenue or of profit; increase in the value for shareholders; significant growth in products; and major new deals.
Archimedes won for a number of reasons. The Company’s lead development product is NasalFent, an fentanyl citrate nasal spray, for the rapid release of breakthrough cancer pain, based on Archimedes’ PecSys™ technology. Archimedes has completed a full phase III programme for NasalFent. The judges were impressed with the filing of a regulatory dossier with EMEA and a US NDA filing in September, all against the backdrop of establishing a profitable, growing, commercial company.
Richard de Souza, CEO of Archimedes Pharma, said: “2009 has been a tough year for the life sciences sector, but against this backdrop we have worked extremely hard to meet key milestones for the company and its shareholders. It is extremely rewarding to see this recognised by Scrip and we look towards 2010 with great confidence.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.